<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564900</url>
  </required_header>
  <id_info>
    <org_study_id>DS8201-A-J101</org_study_id>
    <secondary_id>152978</secondary_id>
    <nct_id>NCT02564900</nct_id>
  </id_info>
  <brief_title>Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors</brief_title>
  <official_title>Phase 1, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study of DS-8201A, in Subjects With Advanced Solid Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, two-part, multicenter study to evaluate the safety and tolerability of&#xD;
      DS-8201a in participants with advanced solid malignant tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Actual">February 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)</measure>
    <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
    <description>Objective response rate (ORR) by independent central review was defined as the proportion of participants who achieve either complete response [CR] or partial response [PR] per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)</measure>
    <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
    <description>Disease control rate (DCR) by independent central review was calculated as the proportion of participants demonstrating complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 6 weeks (Â±1week) from the first dosing date. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)</measure>
    <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
    <description>Best overall response by independent central review was defined as the proportion of participants who achieved either complete response [CR], partial response [PR], stable disease (SD), progressive disease (PD), or were non-evaluable (NE) as per RECIST v1.1. CR was defined as a disappearance of all target lesions, PR at least a 30% decrease in the sum of diameters of target lesions, and SD as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)</measure>
    <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
    <description>Duration of response (DoR) by independent central review was defined as the time between the date of the first complete response (CR) or partial response (PR) until the date of the first documentation of progressive disease (PD) or death due to any cause. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and PD as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)</measure>
    <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
    <description>Time to response (TTR) by independent central review was defined as the time interval between the date of registration until the date at which the criteria were first met for complete response (CR) or partial response (PR). Only participants who achieved CR or PR were included in the TTR analysis. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)</measure>
    <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
    <description>Progression-free survival (PFS) by independent central review was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Among Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)</measure>
    <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
    <description>Overall survival (OS) by independent central review was defined as the time interval from the date of enrollment to the date of death from any cause. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Analysis: Area Under the Concentration Versus Time Curve (AUC) of Serum DS-8201a Following First Dose</measure>
    <time_frame>Post first dose up to Day 147</time_frame>
    <description>The serum PK parameters of DS-8201a and its analytes for area under the concentration-versus-time curve from time 0 to the last quantifiable concentration as calculated by the linear-up log-down trapezoidal method (AUClast) and AUC from time 0 to infinity (AUCinf) elimination rate constant associated with the terminal phase were estimated using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis: Maximum (Peak) Observed Serum Concentration (Cmax) of Serum DS-8201a Following First Dose</measure>
    <time_frame>Post first dose up to Day 147</time_frame>
    <description>The serum PK parameters Maximum (peak) Observed serum concentration of DS-8201a and its analytes were estimated using standard non-compartmental method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis: Time of Maximum Plasma Concentration (Tmax) of Serum DS-8201a Following First Dose</measure>
    <time_frame>Post first dose up to Day 147</time_frame>
    <description>The serum PK parameters of Time of maximum plasma concentration (Tmax) for DS-8201a and its analytes were estimated using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) of Serum DS-8201a Following First Dose</measure>
    <time_frame>Post first dose up to Day 147</time_frame>
    <description>The serum PK parameters of Terminal elimination half-life for DS-8201a and its analytes was estimated using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overview of Treatment-emergent Adverse Events</measure>
    <time_frame>Baseline up to 28 days after the last dose of study drug, up to 3 years 5 months</time_frame>
    <description>Treatment-emergent adverse events were graded by Common Terminology Criteria for Adverse Events, v4.03.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">292</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part 1 Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 is a dose escalation to identify the Maximum Tolerated dose (MTD) or the recommended phase 2 dose of DS-8201a guided by the modified continuous reassessment method using a Bayesian logistic regression model following escalation with overdose control principal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2 is a dose expansion to examine the safety and efficacy of DS-8201a and it is consist of multiple cohorts: in subjects with trastuzumab emtansine (T-DM1)-treated HER2 overexpressing breast cancer (Part 2a); trastuzumab-treated HER2 overexpressing gastric or gastroesophageal junction adenocarcinoma (Part 2b); HER2 low expressing breast cancer (Part 2c), HER2 expressing other solid malignant tumor (Part 2d); HER2 expressing breast cancer (Japan only; Part 2e)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-8201a (FL-DP1)</intervention_name>
    <description>DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (50 mg/2.5 mL) to be administered via intravenous (IV) dose. DS-8201a (FL-DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.</description>
    <arm_group_label>Part 1 Dose escalation</arm_group_label>
    <arm_group_label>Part 2 Dose expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-8201a (FL-DP2)</intervention_name>
    <description>DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered via intravenous (IV) dose. DS-8201a (FL-DP2) was used only used for Dose Expansion Part 2e.</description>
    <arm_group_label>Part 2 Dose expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status( PS) of 0 or 1.&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) â¥ 50%&#xD;
&#xD;
        Part 1:&#xD;
&#xD;
          -  Advanced/unresectable or metastatic breast cancer or gastric or gastroesophageal&#xD;
             junction adenocarcinoma that is refractory to or intolerable with standard treatment,&#xD;
             or for which no standard treatment is available.&#xD;
&#xD;
        Part 2a:&#xD;
&#xD;
          -  Advanced breast cancer with HER2 overexpression that is refractory to or intolerable&#xD;
             with standard treatment, or for which no standard treatment is available.&#xD;
&#xD;
          -  Treated with ado-trastuzumab emtansine (T-DM1)&#xD;
&#xD;
        Part 2b:&#xD;
&#xD;
          -  Advanced gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression&#xD;
             that is refractory to or intolerable with standard treatment, or for which no standard&#xD;
             treatment is available.&#xD;
&#xD;
          -  Treated with trastuzumab&#xD;
&#xD;
        Part 2c:&#xD;
&#xD;
          -  Advanced breast cancer with HER2 low expression that is refractory to or intolerable&#xD;
             with standard treatment, or for which no standard treatment is available.&#xD;
&#xD;
        Part 2d:&#xD;
&#xD;
          -  Satisfy at least one of the following criteria&#xD;
&#xD;
               1. Advanced/unresectable or metastatic solid malignant tumor with HER2 expression&#xD;
                  other than breast cancer and gastric or gastroesophageal junction adenocarcinoma&#xD;
                  that is refractory to or intolerable with standard treatment, or for which no&#xD;
                  standard treatment is available.&#xD;
&#xD;
               2. Advanced/unresectable or metastatic tumor with HER2 mutation that is refractory&#xD;
                  to or intolerable with standard treatment, or for which no standard treatment is&#xD;
                  available.&#xD;
&#xD;
        Part 2e:&#xD;
&#xD;
          -  Advanced breast cancer with HER2 overexpression that is refractory to or intolerable&#xD;
             with standard treatment, or for which no standard treatment is available.&#xD;
&#xD;
          -  Treated with ado-trastuzumab emtansine (T-DM1) (patients with HER2 overexpression&#xD;
             only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a medical history of symptomatic Congestive Heart Failure (CHF) (NYHA classes&#xD;
             II-IV) or serious cardiac arrhythmia.&#xD;
&#xD;
          -  Has a medical history of myocardial infarction or unstable angina.&#xD;
&#xD;
          -  Has a QTc prolongation to &gt; 450 millisecond (ms) in males and &gt; 470 ms in females.&#xD;
&#xD;
          -  Has a medical history of clinically significant lung diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Health Clinical Trials Office</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas M. D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Social Medical Corporation Hakuaikai Sagara Hospital</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of Japanese Foundation For Cancer Research</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/32213540/</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Tsurutani J, Iwata H, Krop I, JÃ¤nne PA, Doi T, Takahashi S, Park H, Redfern C, Tamura K, Wise-Draper TM, Saito K, Sugihara M, Singh J, Jikoh T, Gallant G, Li BT. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discov. 2020 May;10(5):688-701. doi: 10.1158/2159-8290.CD-19-1014. Epub 2020 Mar 25. Erratum in: Cancer Discov. 2020 Jul;10(7):1078.</citation>
    <PMID>32213540</PMID>
  </results_reference>
  <results_reference>
    <citation>Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29. Erratum in: Lancet Oncol. 2019 May 10;:.</citation>
    <PMID>31047803</PMID>
  </results_reference>
  <results_reference>
    <citation>Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):827-836. doi: 10.1016/S1470-2045(19)30088-9. Epub 2019 Apr 29. Erratum in: Lancet Oncol. 2019 May 10;:.</citation>
    <PMID>31047804</PMID>
  </results_reference>
  <results_reference>
    <citation>Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.</citation>
    <PMID>31825192</PMID>
  </results_reference>
  <results_reference>
    <citation>Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017 Nov;18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6. Epub 2017 Oct 13.</citation>
    <PMID>29037983</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <results_first_submitted>July 14, 2020</results_first_submitted>
  <results_first_submitted_qc>June 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2021</results_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumors</keyword>
  <keyword>phase 1</keyword>
  <keyword>oncology</keyword>
  <keyword>HER2</keyword>
  <keyword>Antibody drug conjugate (ADC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02564900/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 292 participants who met all inclusion and no exclusion criteria were enrolled at 8 centers in the US and 6 centers in Japan. A total of 27 participants started the Dose Escalation phase and a total of 265 participants in the Dose Expansion phase.</recruitment_details>
      <pre_assignment_details>The Dose Escalation was intended to identify the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of DS-8201a with at least 3 participants evaluable for assessment of dose-limiting toxicity per dose level. Since the MTD was not reached, doses of 5.4 mg/kg and 6.4 mg/kg were chosen for evaluation in the Dose Expansion phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose Escalation: Cohort 1, 0.8 mg/kg</title>
          <description>Participants in Cohort 1 received an intravenous 0.8 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P2">
          <title>Dose Escalation: Cohort 2, 1.6 mg/kg</title>
          <description>Participants in Cohort 2 received an intravenous 1.6 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P3">
          <title>Dose Escalation: Cohort 3, 3.2 mg/kg</title>
          <description>Participants in Cohort 3 received an intravenous 3.2 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P4">
          <title>Dose Escalation: Cohort 4, 5.4 mg/kg</title>
          <description>Participants in Cohort 4 received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P5">
          <title>Dose Escalation: Cohort 5, 6.4 mg/kg</title>
          <description>Participants in Cohort 5 received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P6">
          <title>Dose Escalation: Cohort 6, 8.0 mg/kg</title>
          <description>Participants in Cohort 6 received an intravenous 8.0 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P7">
          <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
          <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P8">
          <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
          <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P9">
          <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
          <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P10">
          <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
          <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P11">
          <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
          <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P12">
          <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
          <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P13">
          <title>Dose Expansion: HER2-expressing NSCLC Tumors</title>
          <description>Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P14">
          <title>Dose Expansion: HER2-expressing Colorectal Tumors</title>
          <description>Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="P15">
          <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
          <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dose Escalation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease per RECIST</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Dose Expansion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="49"/>
                <participants group_id="P8" count="62"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="33"/>
                <participants group_id="P11" count="17"/>
                <participants group_id="P12" count="24"/>
                <participants group_id="P13" count="18"/>
                <participants group_id="P14" count="20"/>
                <participants group_id="P15" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled, But Not Dosed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="49"/>
                <participants group_id="P8" count="62"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="33"/>
                <participants group_id="P11" count="17"/>
                <participants group_id="P12" count="24"/>
                <participants group_id="P13" count="18"/>
                <participants group_id="P14" count="20"/>
                <participants group_id="P15" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease per RECIST</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="17"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="16"/>
                <participants group_id="P11" count="13"/>
                <participants group_id="P12" count="19"/>
                <participants group_id="P13" count="10"/>
                <participants group_id="P14" count="13"/>
                <participants group_id="P15" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="22"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="11"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="11"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographic and baseline characteristics were assessed in the Enrolled Analysis Set (Dose Escalation, n=27; Dose Expansion, n=265).</population>
      <group_list>
        <group group_id="B1">
          <title>Dose Escalation: Cohort 1, 0.8 mg/kg</title>
          <description>Participants in Cohort 1 received an intravenous 0.8 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B2">
          <title>Dose Escalation: Cohort 2, 1.6 mg/kg</title>
          <description>Participants in Cohort 2 received an intravenous 1.6 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B3">
          <title>Dose Escalation: Cohort 3, 3.2 mg/kg</title>
          <description>Participants in Cohort 3 received an intravenous 3.2 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B4">
          <title>Dose Escalation: Cohort 4, 5.4 mg/kg</title>
          <description>Participants in Cohort 4 received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B5">
          <title>Dose Escalation: Cohort 5, 6.4 mg/kg</title>
          <description>Participants in Cohort 5 received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B6">
          <title>Dose Escalation: Cohort 6, 8.0 mg/kg</title>
          <description>Participants in Cohort 6 received an intravenous 8.0 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B7">
          <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
          <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B8">
          <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
          <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B9">
          <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
          <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B10">
          <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
          <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B11">
          <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
          <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B12">
          <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
          <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B13">
          <title>Dose Expansion: HER2-expressing NSCLC Tumors</title>
          <description>Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B14">
          <title>Dose Expansion: HER2-expressing Colorectal Tumors</title>
          <description>Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B15">
          <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
          <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="B16">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="49"/>
            <count group_id="B8" value="62"/>
            <count group_id="B9" value="20"/>
            <count group_id="B10" value="33"/>
            <count group_id="B11" value="17"/>
            <count group_id="B12" value="24"/>
            <count group_id="B13" value="18"/>
            <count group_id="B14" value="20"/>
            <count group_id="B15" value="22"/>
            <count group_id="B16" value="292"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="33"/>
                    <measurement group_id="B8" value="48"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="25"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="12"/>
                    <measurement group_id="B14" value="16"/>
                    <measurement group_id="B15" value="16"/>
                    <measurement group_id="B16" value="191"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="11"/>
                    <measurement group_id="B12" value="16"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="7.09"/>
                    <measurement group_id="B2" value="66.3" spread="4.73"/>
                    <measurement group_id="B3" value="48.3" spread="14.57"/>
                    <measurement group_id="B4" value="66.8" spread="14.82"/>
                    <measurement group_id="B5" value="58.2" spread="10.40"/>
                    <measurement group_id="B6" value="66.2" spread="10.67"/>
                    <measurement group_id="B7" value="56.2" spread="12.11"/>
                    <measurement group_id="B8" value="54.9" spread="10.28"/>
                    <measurement group_id="B9" value="57.8" spread="9.68"/>
                    <measurement group_id="B10" value="56.3" spread="10.97"/>
                    <measurement group_id="B11" value="64.2" spread="11.00"/>
                    <measurement group_id="B12" value="66.2" spread="8.55"/>
                    <measurement group_id="B13" value="57.4" spread="15.29"/>
                    <measurement group_id="B14" value="59.5" spread="9.90"/>
                    <measurement group_id="B15" value="58.5" spread="10.16"/>
                    <measurement group_id="B16" value="58.1" spread="11.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="48"/>
                    <measurement group_id="B8" value="62"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="33"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="13"/>
                    <measurement group_id="B14" value="9"/>
                    <measurement group_id="B15" value="9"/>
                    <measurement group_id="B16" value="229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="20"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="11"/>
                    <measurement group_id="B15" value="13"/>
                    <measurement group_id="B16" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="25"/>
                    <measurement group_id="B8" value="40"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="23"/>
                    <measurement group_id="B11" value="11"/>
                    <measurement group_id="B12" value="24"/>
                    <measurement group_id="B13" value="9"/>
                    <measurement group_id="B14" value="17"/>
                    <measurement group_id="B15" value="14"/>
                    <measurement group_id="B16" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="7"/>
                    <measurement group_id="B16" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="16"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="10"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="9"/>
                    <measurement group_id="B16" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="37"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="22"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="24"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="17"/>
                    <measurement group_id="B15" value="13"/>
                    <measurement group_id="B16" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)</title>
        <description>Objective response rate (ORR) by independent central review was defined as the proportion of participants who achieve either complete response [CR] or partial response [PR] per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
        <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
        <population>ORR was assessed among participants in the Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation: Cohort 1, 0.8 mg/kg</title>
            <description>Participants in Cohort 1 received an intravenous 0.8 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation: Cohort 2, 1.6 mg/kg</title>
            <description>Participants in Cohort 2 received an intravenous 1.6 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation: Cohort 3, 3.2 mg/kg</title>
            <description>Participants in Cohort 3 received an intravenous 3.2 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation: Cohort 4, 5.4 mg/kg</title>
            <description>Participants in Cohort 4 received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation: Cohort 5, 6.4 mg/kg</title>
            <description>Participants in Cohort 5 received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation: Cohort 6, 8.0 mg/kg</title>
            <description>Participants in Cohort 6 received an intravenous 8.0 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O7">
            <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O8">
            <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O9">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O10">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O11">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O12">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O13">
            <title>Dose Expansion: HER2-expressing NSCLC Tumors</title>
            <description>Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O14">
            <title>Dose Expansion: HER2-expressing Colorectal Tumors</title>
            <description>Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O15">
            <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
            <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)</title>
          <description>Objective response rate (ORR) by independent central review was defined as the proportion of participants who achieve either complete response [CR] or partial response [PR] per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
          <population>ORR was assessed among participants in the Intent-to-Treat Analysis Set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="67"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="33"/>
                <count group_id="O11" value="19"/>
                <count group_id="O12" value="25"/>
                <count group_id="O13" value="18"/>
                <count group_id="O14" value="20"/>
                <count group_id="O15" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O2" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O4" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O5" value="33.3" lower_limit="4.3" upper_limit="77.7"/>
                    <measurement group_id="O6" value="50.0" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O7" value="51.0" lower_limit="36.6" upper_limit="65.2"/>
                    <measurement group_id="O8" value="53.7" lower_limit="41.1" upper_limit="66.0"/>
                    <measurement group_id="O9" value="33.3" lower_limit="14.6" upper_limit="57.0"/>
                    <measurement group_id="O10" value="39.4" lower_limit="22.9" upper_limit="57.9"/>
                    <measurement group_id="O11" value="26.3" lower_limit="9.1" upper_limit="51.2"/>
                    <measurement group_id="O12" value="32.0" lower_limit="14.9" upper_limit="53.5"/>
                    <measurement group_id="O13" value="55.6" lower_limit="30.8" upper_limit="78.5"/>
                    <measurement group_id="O14" value="5.0" lower_limit="0.1" upper_limit="24.9"/>
                    <measurement group_id="O15" value="30.4" lower_limit="13.2" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)</title>
        <description>Disease control rate (DCR) by independent central review was calculated as the proportion of participants demonstrating complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 6 weeks (Â±1week) from the first dosing date. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.</description>
        <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
        <population>DCR was assessed in the Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation: Cohort 1, 0.8 mg/kg</title>
            <description>Participants in Cohort 1 received an intravenous 0.8 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation: Cohort 2, 1.6 mg/kg</title>
            <description>Participants in Cohort 2 received an intravenous 1.6 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation: Cohort 3, 3.2 mg/kg</title>
            <description>Participants in Cohort 3 received an intravenous 3.2 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation: Cohort 4, 5.4 mg/kg</title>
            <description>Participants in Cohort 4 received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation: Cohort 5, 6.4 mg/kg</title>
            <description>Participants in Cohort 5 received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation: Cohort 6, 8.0 mg/kg</title>
            <description>Participants in Cohort 6 received an intravenous 8.0 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O7">
            <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O8">
            <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O9">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O10">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O11">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O12">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O13">
            <title>Dose Expansion: HER2-expressing NSCLC Tumors</title>
            <description>Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O14">
            <title>Dose Expansion: HER2-expressing Colorectal Tumors</title>
            <description>Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O15">
            <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
            <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)</title>
          <description>Disease control rate (DCR) by independent central review was calculated as the proportion of participants demonstrating complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 6 weeks (Â±1week) from the first dosing date. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.</description>
          <population>DCR was assessed in the Intent-to-Treat Analysis Set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="67"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="33"/>
                <count group_id="O11" value="19"/>
                <count group_id="O12" value="25"/>
                <count group_id="O13" value="18"/>
                <count group_id="O14" value="20"/>
                <count group_id="O15" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                    <measurement group_id="O4" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O7" value="88.2" lower_limit="76.1" upper_limit="95.6"/>
                    <measurement group_id="O8" value="95.5" lower_limit="87.5" upper_limit="99.1"/>
                    <measurement group_id="O9" value="85.7" lower_limit="63.7" upper_limit="97.0"/>
                    <measurement group_id="O10" value="87.9" lower_limit="71.8" upper_limit="96.6"/>
                    <measurement group_id="O11" value="78.9" lower_limit="54.4" upper_limit="93.9"/>
                    <measurement group_id="O12" value="88.0" lower_limit="68.8" upper_limit="97.5"/>
                    <measurement group_id="O13" value="83.3" lower_limit="58.6" upper_limit="96.4"/>
                    <measurement group_id="O14" value="80.0" lower_limit="56.3" upper_limit="94.3"/>
                    <measurement group_id="O15" value="82.6" lower_limit="61.2" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)</title>
        <description>Best overall response by independent central review was defined as the proportion of participants who achieved either complete response [CR], partial response [PR], stable disease (SD), progressive disease (PD), or were non-evaluable (NE) as per RECIST v1.1. CR was defined as a disappearance of all target lesions, PR at least a 30% decrease in the sum of diameters of target lesions, and SD as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.</description>
        <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
        <population>Best overall response was assessed in the Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation: Cohort 1, 0.8 mg/kg</title>
            <description>Participants in Cohort 1 received an intravenous 0.8 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation: Cohort 2, 1.6 mg/kg</title>
            <description>Participants in Cohort 2 received an intravenous 1.6 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation: Cohort 3, 3.2 mg/kg</title>
            <description>Participants in Cohort 3 received an intravenous 3.2 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation: Cohort 4, 5.4 mg/kg</title>
            <description>Participants in Cohort 4 received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation: Cohort 5, 6.4 mg/kg</title>
            <description>Participants in Cohort 5 received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation: Cohort 6, 8.0 mg/kg</title>
            <description>Participants in Cohort 6 received an intravenous 8.0 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O7">
            <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O8">
            <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O9">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O10">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O11">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O12">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O13">
            <title>Dose Expansion: HER2-expressing NSCLC Tumors</title>
            <description>Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O14">
            <title>Dose Expansion: HER2-expressing Colorectal Tumors</title>
            <description>Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O15">
            <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
            <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)</title>
          <description>Best overall response by independent central review was defined as the proportion of participants who achieved either complete response [CR], partial response [PR], stable disease (SD), progressive disease (PD), or were non-evaluable (NE) as per RECIST v1.1. CR was defined as a disappearance of all target lesions, PR at least a 30% decrease in the sum of diameters of target lesions, and SD as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included 8 participants with salivary/submandibular/parotid gland, 2 breast with HER2-mutation, 2 endometrial, 2 esophageal, 2 Paget's disease, 1 cholangiocarcinoma, 1 extraskeletal myxoide chondrosarcoma, 1 gallbladder, 1 pancreatic, 1 small intestine, 1 uterine cervix, and 1 participant who received 5.4 mg/kg with HER2-low gastric/GEJ cancer.</description>
          <population>Best overall response was assessed in the Intent-to-Treat Analysis Set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="67"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="33"/>
                <count group_id="O11" value="19"/>
                <count group_id="O12" value="25"/>
                <count group_id="O13" value="18"/>
                <count group_id="O14" value="20"/>
                <count group_id="O15" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="28"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="13"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="7"/>
                    <measurement group_id="O13" value="10"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="28"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="16"/>
                    <measurement group_id="O11" value="10"/>
                    <measurement group_id="O12" value="14"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="15"/>
                    <measurement group_id="O15" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)</title>
        <description>Duration of response (DoR) by independent central review was defined as the time between the date of the first complete response (CR) or partial response (PR) until the date of the first documentation of progressive disease (PD) or death due to any cause. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and PD as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
        <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
        <population>DoR was assessed among participants who achieved a CR or PR in the Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O2">
            <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O3">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O4">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O5">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O6">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O7">
            <title>Dose Expansion: HER2-expressing NSCLC Tumors</title>
            <description>Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O8">
            <title>Dose Expansion: HER2-expressing Colorectal Tumors</title>
            <description>Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O9">
            <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
            <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)</title>
          <description>Duration of response (DoR) by independent central review was defined as the time between the date of the first complete response (CR) or partial response (PR) until the date of the first documentation of progressive disease (PD) or death due to any cause. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and PD as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
          <population>DoR was assessed among participants who achieved a CR or PR in the Intent-to-Treat Analysis Set.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="6.7" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                    <measurement group_id="O2" value="13.6" lower_limit="7.3" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Lack of a median value is due to less than 50% of the participants experiencing the event. In a Kaplan-Meier analysis, the curve would never fall below the 50% mark, and would continue to the largest observed censored time value.</measurement>
                    <measurement group_id="O4" value="10.4" lower_limit="3.4" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                    <measurement group_id="O5" value="5.6" lower_limit="2.9" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                    <measurement group_id="O6" value="6.9" lower_limit="3.5" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                    <measurement group_id="O7" value="10.7" lower_limit="6.9" upper_limit="11.5"/>
                    <measurement group_id="O8" value="13.4" lower_limit="NA" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="3.0" upper_limit="NA">Median and 95% confidence interval were not calculable due to insufficient number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response (TTR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)</title>
        <description>Time to response (TTR) by independent central review was defined as the time interval between the date of registration until the date at which the criteria were first met for complete response (CR) or partial response (PR). Only participants who achieved CR or PR were included in the TTR analysis. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
        <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
        <population>Time to response was assessed among participants who achieved CR or PR in the Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O2">
            <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O3">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O4">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O5">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O6">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O7">
            <title>Dose Expansion: HER2-expressing NSCLC Tumors</title>
            <description>Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O8">
            <title>Dose Expansion: HER2-expressing Colorectal Tumors</title>
            <description>Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O9">
            <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
            <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response (TTR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)</title>
          <description>Time to response (TTR) by independent central review was defined as the time interval between the date of registration until the date at which the criteria were first met for complete response (CR) or partial response (PR). Only participants who achieved CR or PR were included in the TTR analysis. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
          <population>Time to response was assessed among participants who achieved CR or PR in the Intent-to-Treat Analysis Set.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.5" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.4" upper_limit="2.9"/>
                    <measurement group_id="O3" value="2.6" lower_limit="1.2" upper_limit="4.2"/>
                    <measurement group_id="O4" value="2.7" lower_limit="1.2" upper_limit="3.1"/>
                    <measurement group_id="O5" value="1.6" lower_limit="1.2" upper_limit="3.1"/>
                    <measurement group_id="O6" value="2.2" lower_limit="1.4" upper_limit="2.9"/>
                    <measurement group_id="O7" value="1.4" lower_limit="1.2" upper_limit="2.8"/>
                    <measurement group_id="O8" value="3.0" lower_limit="NA" upper_limit="NA">The 95% confidence interval was not calculable due to insufficient number of participants with events.</measurement>
                    <measurement group_id="O9" value="1.6" lower_limit="1.2" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)</title>
        <description>Progression-free survival (PFS) by independent central review was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
        <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
        <population>PFS was assessed in the Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O2">
            <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O3">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O4">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O5">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O6">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O7">
            <title>Dose Expansion: HER2-expressing NSCLC Tumors</title>
            <description>Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O8">
            <title>Dose Expansion: HER2-expressing Colorectal Tumors</title>
            <description>Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O9">
            <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
            <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)</title>
          <description>Progression-free survival (PFS) by independent central review was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
          <population>PFS was assessed in the Intent-to-Treat Analysis Set.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="8.5" upper_limit="19.6"/>
                    <measurement group_id="O2" value="14.1" lower_limit="8.5" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="2.7" upper_limit="NA">Median and 95% confidence interval were not calculable due to insufficient number of participants with events.</measurement>
                    <measurement group_id="O4" value="11.1" lower_limit="5.0" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                    <measurement group_id="O5" value="4.3" lower_limit="2.6" upper_limit="8.6"/>
                    <measurement group_id="O6" value="8.2" lower_limit="4.2" upper_limit="11.0"/>
                    <measurement group_id="O7" value="11.3" lower_limit="7.2" upper_limit="14.3"/>
                    <measurement group_id="O8" value="4.0" lower_limit="2.7" upper_limit="5.6"/>
                    <measurement group_id="O9" value="11.0" lower_limit="2.8" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Among Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)</title>
        <description>Overall survival (OS) by independent central review was defined as the time interval from the date of enrollment to the date of death from any cause. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
        <time_frame>From 6 months postdose of last participant up to 3 years 5 months</time_frame>
        <population>OS was assessed in the Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O2">
            <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O3">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O4">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O5">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O6">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O7">
            <title>Dose Expansion: HER2-expressing NSCLC Tumors</title>
            <description>Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O8">
            <title>Dose Expansion: HER2-expressing Colorectal Tumors</title>
            <description>Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O9">
            <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
            <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Among Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)</title>
          <description>Overall survival (OS) by independent central review was defined as the time interval from the date of enrollment to the date of death from any cause. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.</description>
          <population>OS was assessed in the Intent-to-Treat Analysis Set.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Lack of median value is due to less than 50% of the participants experiencing the event. In a Kaplan-Meier analysis, the curve would never fall below the 50% mark, and would continue to the largest observed censored time value.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="26.4" upper_limit="NA">Median and 95% confidence interval were not calculable due to insufficient number of participants with events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Lack of median value is due to less than 50% of the participants experiencing the event. In a Kaplan-Meier analysis, the curve would never fall below the 50% mark, and would continue to the largest observed censored time value.</measurement>
                    <measurement group_id="O4" value="19.7" lower_limit="12.5" upper_limit="29.4"/>
                    <measurement group_id="O5" value="18.9" lower_limit="5.7" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                    <measurement group_id="O6" value="26.2" lower_limit="10.0" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="17.3" upper_limit="NA">Median and 95% confidence interval were not calculable due to insufficient number of participants with events.</measurement>
                    <measurement group_id="O8" value="15.6" lower_limit="4.8" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                    <measurement group_id="O9" value="23.4" lower_limit="9.7" upper_limit="NA">Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Analysis: Area Under the Concentration Versus Time Curve (AUC) of Serum DS-8201a Following First Dose</title>
        <description>The serum PK parameters of DS-8201a and its analytes for area under the concentration-versus-time curve from time 0 to the last quantifiable concentration as calculated by the linear-up log-down trapezoidal method (AUClast) and AUC from time 0 to infinity (AUCinf) elimination rate constant associated with the terminal phase were estimated using standard non-compartmental methods.</description>
        <time_frame>Post first dose up to Day 147</time_frame>
        <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation: Cohort 1, 0.8 mg/kg</title>
            <description>Participants in Cohort 1 received an intravenous 0.8 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation: Cohort 2, 1.6 mg/kg</title>
            <description>Participants in Cohort 2 received an intravenous 1.6 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation: Cohort 3, 3.2 mg/kg</title>
            <description>Participants in Cohort 3 received an intravenous 3.2 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation: Cohort 4, 5.4 mg/kg</title>
            <description>Participants in Cohort 4 received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation: Cohort 5, 6.4 mg/kg</title>
            <description>Participants in Cohort 5 received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation: Cohort 6, 8.0 mg/kg</title>
            <description>Participants in Cohort 6 received an intravenous 8.0 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O7">
            <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O8">
            <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O9">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O10">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O11">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O12">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O13">
            <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
            <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O14">
            <title>Dose Expansion: HER2-expressing Breast Cancer</title>
            <description>Japan only: Participants with HER2-expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP2).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Analysis: Area Under the Concentration Versus Time Curve (AUC) of Serum DS-8201a Following First Dose</title>
          <description>The serum PK parameters of DS-8201a and its analytes for area under the concentration-versus-time curve from time 0 to the last quantifiable concentration as calculated by the linear-up log-down trapezoidal method (AUClast) and AUC from time 0 to infinity (AUCinf) elimination rate constant associated with the terminal phase were estimated using standard non-compartmental methods.</description>
          <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
          <units>ug*d/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="50"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="19"/>
                <count group_id="O11" value="17"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUClast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="50"/>
                    <count group_id="O9" value="20"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="17"/>
                    <count group_id="O12" value="23"/>
                    <count group_id="O13" value="58"/>
                    <count group_id="O14" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="13.1"/>
                    <measurement group_id="O2" value="116" spread="58.7"/>
                    <measurement group_id="O3" value="325" spread="142"/>
                    <measurement group_id="O4" value="544" spread="165"/>
                    <measurement group_id="O5" value="901" spread="155"/>
                    <measurement group_id="O6" value="996" spread="229"/>
                    <measurement group_id="O7" value="559" spread="178"/>
                    <measurement group_id="O8" value="785" spread="228"/>
                    <measurement group_id="O9" value="581" spread="180"/>
                    <measurement group_id="O10" value="693" spread="178"/>
                    <measurement group_id="O11" value="542" spread="163"/>
                    <measurement group_id="O12" value="507" spread="126"/>
                    <measurement group_id="O13" value="631" spread="184"/>
                    <measurement group_id="O14" value="693" spread="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCinfinity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="49"/>
                    <count group_id="O9" value="19"/>
                    <count group_id="O10" value="17"/>
                    <count group_id="O11" value="17"/>
                    <count group_id="O12" value="22"/>
                    <count group_id="O13" value="58"/>
                    <count group_id="O14" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" spread="11.9"/>
                    <measurement group_id="O2" value="121" spread="58.9"/>
                    <measurement group_id="O3" value="340" spread="150"/>
                    <measurement group_id="O4" value="590" spread="186"/>
                    <measurement group_id="O5" value="1030" spread="209"/>
                    <measurement group_id="O6" value="1100" spread="259"/>
                    <measurement group_id="O7" value="602" spread="203"/>
                    <measurement group_id="O8" value="848" spread="243"/>
                    <measurement group_id="O9" value="589" spread="145"/>
                    <measurement group_id="O10" value="762" spread="205"/>
                    <measurement group_id="O11" value="596" spread="183"/>
                    <measurement group_id="O12" value="563" spread="151"/>
                    <measurement group_id="O13" value="683" spread="209"/>
                    <measurement group_id="O14" value="753" spread="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Analysis: Maximum (Peak) Observed Serum Concentration (Cmax) of Serum DS-8201a Following First Dose</title>
        <description>The serum PK parameters Maximum (peak) Observed serum concentration of DS-8201a and its analytes were estimated using standard non-compartmental method.</description>
        <time_frame>Post first dose up to Day 147</time_frame>
        <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation: Cohort 1, 0.8 mg/kg</title>
            <description>Participants in Cohort 1 received an intravenous 0.8 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation: Cohort 2, 1.6 mg/kg</title>
            <description>Participants in Cohort 2 received an intravenous 1.6 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation: Cohort 3, 3.2 mg/kg</title>
            <description>Participants in Cohort 3 received an intravenous 3.2 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation: Cohort 4, 5.4 mg/kg</title>
            <description>Participants in Cohort 4 received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation: Cohort 5, 6.4 mg/kg</title>
            <description>Participants in Cohort 5 received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation: Cohort 6, 8.0 mg/kg</title>
            <description>Participants in Cohort 6 received an intravenous 8.0 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O7">
            <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O8">
            <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O9">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O10">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O11">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O12">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O13">
            <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
            <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O14">
            <title>Dose Expansion: HER2-expressing Breast Cancer</title>
            <description>Japan only: Participants with HER2-expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP2).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Analysis: Maximum (Peak) Observed Serum Concentration (Cmax) of Serum DS-8201a Following First Dose</title>
          <description>The serum PK parameters Maximum (peak) Observed serum concentration of DS-8201a and its analytes were estimated using standard non-compartmental method.</description>
          <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="50"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="19"/>
                <count group_id="O11" value="17"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="59"/>
                <count group_id="O14" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" spread="3.76"/>
                    <measurement group_id="O2" value="36.2" spread="4.98"/>
                    <measurement group_id="O3" value="78.2" spread="16.1"/>
                    <measurement group_id="O4" value="127" spread="17.2"/>
                    <measurement group_id="O5" value="181" spread="33.1"/>
                    <measurement group_id="O6" value="221" spread="41.0"/>
                    <measurement group_id="O7" value="126" spread="37.7"/>
                    <measurement group_id="O8" value="170" spread="53.6"/>
                    <measurement group_id="O9" value="133" spread="18.3"/>
                    <measurement group_id="O10" value="155" spread="33.2"/>
                    <measurement group_id="O11" value="113" spread="30.0"/>
                    <measurement group_id="O12" value="116" spread="21.1"/>
                    <measurement group_id="O13" value="150" spread="30.3"/>
                    <measurement group_id="O14" value="155" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Analysis: Time of Maximum Plasma Concentration (Tmax) of Serum DS-8201a Following First Dose</title>
        <description>The serum PK parameters of Time of maximum plasma concentration (Tmax) for DS-8201a and its analytes were estimated using standard non-compartmental methods.</description>
        <time_frame>Post first dose up to Day 147</time_frame>
        <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation: Cohort 1, 0.8 mg/kg</title>
            <description>Participants in Cohort 1 received an intravenous 0.8 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation: Cohort 2, 1.6 mg/kg</title>
            <description>Participants in Cohort 2 received an intravenous 1.6 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation: Cohort 3, 3.2 mg/kg</title>
            <description>Participants in Cohort 3 received an intravenous 3.2 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation: Cohort 4, 5.4 mg/kg</title>
            <description>Participants in Cohort 4 received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation: Cohort 5, 6.4 mg/kg</title>
            <description>Participants in Cohort 5 received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation: Cohort 6, 8.0 mg/kg</title>
            <description>Participants in Cohort 6 received an intravenous 8.0 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O7">
            <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O8">
            <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O9">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O10">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O11">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O12">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O13">
            <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
            <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O14">
            <title>Dose Expansion: HER2-expressing Breast Cancer</title>
            <description>Japan only: Participants with HER2-expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP2).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Analysis: Time of Maximum Plasma Concentration (Tmax) of Serum DS-8201a Following First Dose</title>
          <description>The serum PK parameters of Time of maximum plasma concentration (Tmax) for DS-8201a and its analytes were estimated using standard non-compartmental methods.</description>
          <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="50"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="19"/>
                <count group_id="O11" value="17"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="59"/>
                <count group_id="O14" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" lower_limit="1.62" upper_limit="1.98"/>
                    <measurement group_id="O2" value="4.03" lower_limit="1.87" upper_limit="4.08"/>
                    <measurement group_id="O3" value="4.12" lower_limit="1.95" upper_limit="6.88"/>
                    <measurement group_id="O4" value="2.02" lower_limit="1.87" upper_limit="2.07"/>
                    <measurement group_id="O5" value="2.06" lower_limit="1.50" upper_limit="3.97"/>
                    <measurement group_id="O6" value="1.97" lower_limit="1.70" upper_limit="6.80"/>
                    <measurement group_id="O7" value="2.00" lower_limit="1.50" upper_limit="6.85"/>
                    <measurement group_id="O8" value="2.08" lower_limit="1.53" upper_limit="7.05"/>
                    <measurement group_id="O9" value="2.16" lower_limit="1.50" upper_limit="7.07"/>
                    <measurement group_id="O10" value="2.00" lower_limit="1.50" upper_limit="6.67"/>
                    <measurement group_id="O11" value="2.03" lower_limit="1.58" upper_limit="4.08"/>
                    <measurement group_id="O12" value="1.95" lower_limit="1.53" upper_limit="7.00"/>
                    <measurement group_id="O13" value="2.02" lower_limit="1.50" upper_limit="7.20"/>
                    <measurement group_id="O14" value="2.05" lower_limit="1.62" upper_limit="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) of Serum DS-8201a Following First Dose</title>
        <description>The serum PK parameters of Terminal elimination half-life for DS-8201a and its analytes was estimated using standard non-compartmental methods.</description>
        <time_frame>Post first dose up to Day 147</time_frame>
        <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation: Cohort 1, 0.8 mg/kg</title>
            <description>Participants in Cohort 1 received an intravenous 0.8 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation: Cohort 2, 1.6 mg/kg</title>
            <description>Participants in Cohort 2 received an intravenous 1.6 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation: Cohort 3, 3.2 mg/kg</title>
            <description>Participants in Cohort 3 received an intravenous 3.2 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation: Cohort 4, 5.4 mg/kg</title>
            <description>Participants in Cohort 4 received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation: Cohort 5, 6.4 mg/kg</title>
            <description>Participants in Cohort 5 received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation: Cohort 6, 8.0 mg/kg</title>
            <description>Participants in Cohort 6 received an intravenous 8.0 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O7">
            <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O8">
            <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O9">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O10">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O11">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O12">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O13">
            <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
            <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O14">
            <title>Dose Expansion: HER2-expressing Breast Cancer</title>
            <description>Japan only: Participants with HER2-expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP2).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) of Serum DS-8201a Following First Dose</title>
          <description>The serum PK parameters of Terminal elimination half-life for DS-8201a and its analytes was estimated using standard non-compartmental methods.</description>
          <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="49"/>
                <count group_id="O9" value="19"/>
                <count group_id="O10" value="17"/>
                <count group_id="O11" value="17"/>
                <count group_id="O12" value="22"/>
                <count group_id="O13" value="58"/>
                <count group_id="O14" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="0.671"/>
                    <measurement group_id="O2" value="3.07" spread="1.22"/>
                    <measurement group_id="O3" value="4.23" spread="1.24"/>
                    <measurement group_id="O4" value="6.03" spread="0.603"/>
                    <measurement group_id="O5" value="7.33" spread="1.64"/>
                    <measurement group_id="O6" value="6.44" spread="0.793"/>
                    <measurement group_id="O7" value="5.52" spread="1.23"/>
                    <measurement group_id="O8" value="6.00" spread="1.22"/>
                    <measurement group_id="O9" value="5.28" spread="1.49"/>
                    <measurement group_id="O10" value="5.79" spread="1.01"/>
                    <measurement group_id="O11" value="6.18" spread="1.18"/>
                    <measurement group_id="O12" value="5.90" spread="1.57"/>
                    <measurement group_id="O13" value="5.61" spread="1.29"/>
                    <measurement group_id="O14" value="5.46" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overview of Treatment-emergent Adverse Events</title>
        <description>Treatment-emergent adverse events were graded by Common Terminology Criteria for Adverse Events, v4.03.</description>
        <time_frame>Baseline up to 28 days after the last dose of study drug, up to 3 years 5 months</time_frame>
        <population>Safety events were assessed in the Safety Analysis Set. It was prespecified in the protocol that single patients with unique tumor types would be combined into 1 group for the safety analysis. For the safety overview, TEAEs for HER2-expressing NSCLC, Colorectal, and Other Solid Tumors (excluding 1 HER2-low gastric cancer subject who received 5.4 mg/kg) were combined and reported together.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation: Cohort 1, 0.8 mg/kg</title>
            <description>Participants in Cohort 1 received an intravenous 0.8 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation: Cohort 2, 1.6 mg/kg</title>
            <description>Participants in Cohort 2 received an intravenous 1.6 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation: Cohort 3, 3.2 mg/kg</title>
            <description>Participants in Cohort 3 received an intravenous 3.2 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation: Cohort 4, 5.4 mg/kg</title>
            <description>Participants in Cohort 4 received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation: Cohort 5, 6.4 mg/kg</title>
            <description>Participants in Cohort 5 received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation: Cohort 6, 8.0 mg/kg</title>
            <description>Participants in Cohort 6 received an intravenous 8.0 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O7">
            <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O8">
            <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O9">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O10">
            <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
            <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O11">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O12">
            <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
            <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
          <group group_id="O13">
            <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
            <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
          </group>
        </group_list>
        <measure>
          <title>Overview of Treatment-emergent Adverse Events</title>
          <description>Treatment-emergent adverse events were graded by Common Terminology Criteria for Adverse Events, v4.03.</description>
          <population>Safety events were assessed in the Safety Analysis Set. It was prespecified in the protocol that single patients with unique tumor types would be combined into 1 group for the safety analysis. For the safety overview, TEAEs for HER2-expressing NSCLC, Colorectal, and Other Solid Tumors (excluding 1 HER2-low gastric cancer subject who received 5.4 mg/kg) were combined and reported together.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="66"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="33"/>
                <count group_id="O11" value="19"/>
                <count group_id="O12" value="25"/>
                <count group_id="O13" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-emergent adverse events (TEAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="50"/>
                    <measurement group_id="O8" value="66"/>
                    <measurement group_id="O9" value="20"/>
                    <measurement group_id="O10" value="33"/>
                    <measurement group_id="O11" value="19"/>
                    <measurement group_id="O12" value="25"/>
                    <measurement group_id="O13" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="50"/>
                    <measurement group_id="O8" value="66"/>
                    <measurement group_id="O9" value="20"/>
                    <measurement group_id="O10" value="33"/>
                    <measurement group_id="O11" value="18"/>
                    <measurement group_id="O12" value="25"/>
                    <measurement group_id="O13" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs â¥Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="42"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="23"/>
                    <measurement group_id="O11" value="10"/>
                    <measurement group_id="O12" value="20"/>
                    <measurement group_id="O13" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs â¥Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="37"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="20"/>
                    <measurement group_id="O11" value="8"/>
                    <measurement group_id="O12" value="16"/>
                    <measurement group_id="O13" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs (including AEs ending in death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="12"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="7"/>
                    <measurement group_id="O13" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs associated with death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs associated with death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs associated with discontinuation of drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="11"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related TEAEs associated with drug discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="21"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="11"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs associated with dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="9"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="9"/>
                    <measurement group_id="O13" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs associated with dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="9"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="9"/>
                    <measurement group_id="O13" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs associated with dose interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="36"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="13"/>
                    <measurement group_id="O11" value="9"/>
                    <measurement group_id="O12" value="13"/>
                    <measurement group_id="O13" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related TEAEs associated with dose interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="28"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="11"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="11"/>
                    <measurement group_id="O13" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse event (TEAE) data were collected from baseline up to 28 days after the last dose of study drug, up to 3 years 5 months.</time_frame>
      <desc>TEAEs were AEs that occur, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the first dose until 28 days after the last dose. Serious adverse events with an onset or worsening â¥29 days after the last dose, if related to the study treatment, are also TEAEs. TEAEs from other HER2-expressing solid tumors other than breast or gastric were combined as prespecified in the protocol (excluding 1 patient with gastric cancer who received 5.4 mg/kg).</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose Escalation: Cohort 1, 0.8 mg/kg</title>
          <description>Participants in Cohort 1 received an intravenous 0.8 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="E2">
          <title>Dose Escalation: Cohort 2, 1.6 mg/kg</title>
          <description>Participants in Cohort 2 received an intravenous 1.6 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="E3">
          <title>Dose Escalation: Cohort 3, 3.2 mg/kg</title>
          <description>Participants in Cohort 3 received an intravenous 3.2 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="E4">
          <title>Dose Escalation: Cohort 4, 5.4 mg/kg</title>
          <description>Participants in Cohort 4 received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="E5">
          <title>Dose Escalation: Cohort 5, 6.4 mg/kg</title>
          <description>Participants in Cohort 5 received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="E6">
          <title>Dose Escalation: Cohort 6, 8.0 mg/kg</title>
          <description>Participants in Cohort 6 received an intravenous 8.0 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="E7">
          <title>Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg</title>
          <description>Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="E8">
          <title>Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg</title>
          <description>Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="E9">
          <title>Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg</title>
          <description>Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="E10">
          <title>Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg</title>
          <description>Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="E11">
          <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg</title>
          <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="E12">
          <title>Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg</title>
          <description>Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
        <group group_id="E13">
          <title>Dose Expansion: HER2-expressing Other Solid Tumors</title>
          <description>Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="18" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Small intestine obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrointestinal mucosa hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Radiation necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Scleroderma-like reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Central venous catheterisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="50" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="66" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="33" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="59" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="30" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="23" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cold type haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Corneal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="43" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="52" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="26" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="19" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="44" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="35" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="31" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="28" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="19" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="30" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="10" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="32" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="21" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="13" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Influenza-like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Angular cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Infusion-related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="24" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="22" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="25" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="21" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="17" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood creatinine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="47" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="20" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="22" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="35" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Tumour-associated fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemangioma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="45" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="20" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Madarosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nail discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Contact for Clinical Trial Information</name_or_title>
      <organization>Daiichi Sankyo, Inc.</organization>
      <phone>1-908-992-6400</phone>
      <email>CTRinfo@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

